CYTOGNOMIX, Inc.

PERSONALIZED GENOMIC DIAGNOSTIC PRODUCTS

Peter Rogan—President

Dr Rogan is an internationally recognized researcher in human genomics and bioinformatics who has authored more than 100 scientific publications and holds several related patents. As an inventor of SC technology, Dr. Rogan is president of Cytognomix.  Dr. Rogan also founded, Phylogenetix Laboratories, a US company where preliminary development of SC technology occurred under a NIH SBIR grant. Dr. Rogan is currently Professor of Biochemistry at the Schulich School of Medicine and Dentistry, and holds the Canada Research Chair in Genome Bioinformatics. He is committed to the success of the new Ontario company by developing new SC applications and improving the company’s products in his university laboratory and at the Company laboratories at the Stiller Centre. Dr. Rogan received his PhD in Molecular Biophysics and Biochemistry from Yale, and holds degrees from the University of Grenoble and Johns Hopkins.

 

Joan Knoll—Chief Medical Officer

Dr. Knoll is direct Director of the Laboratory of Genomic Disorders, Schulich School of Medicine, at the University of Western Ontario is Professor in Pathology and is certified by the American Board of Medical Genetics in Cytogenetics and Molecular Genetics. She is also Medical Leader of Molecular Pathology at London Health Sciences Center, London Ontario.  She has directed clinical cytogenetics laboratories at several academic research institutions and has authored more than 80 research publications. Dr. Knoll published an early detailed protocol  on in situ hybridization (ISH) that remains widely cited, and continued to develop improvements in ISH, and co-invented SC-Probe technology with Dr. Rogan. Current projects are aimed at precisely defining chromosome abnormalities in chronic myelogenous leukemia and other diseases using SC FISH technology.

 

Glen Smeltzer—Chief Financial Officer

Glen Smeltzer has over 21 years experience working with emerging technology, as a start-up CEO, partner in an early-stage venture capital fund, and a technology company incubator. Mr. Smeltzer also led Advantage Medical, a manufacturer of neurodiagnostic equipment, from start-up and market entry to ultimate profitability and eventual acquisition.  Mr. Smeltzer, as part of the team at Fullarton Capital, managed venture investments in a variety of emerging Canadian technology companies.  He currently serves as interim President of the Stiller Centre for Technology Commercialization in London, and as Director, Engineering and Natural Sciences, at WORLDiscoveries. Mr. Smeltzer holds a Chemical Engineering degree from the University of Waterloo, and an MBA from the Ivey School of Business at the University of Western Ontario.

Shane Climie-Business Development (Popper and Company, Consultants)

Shane Climie, PhD has more than 20 years of R&D and business development experience in the life sciences and pharmaceutical industry. He has led research teams involved in all aspects of drug discovery and has designed, negotiated and managed many R&D collaborations. He has extensive experience in technology evaluation, technology development and strategic planning.
Most recently, Shane held several positions at Protana Inc. (formerly MDS Proteomics) including Senior Vice President of Science Strategy and Business Development, Senior Vice-President of Research Collaborations, and Vice-President of Proteomics and Business Development. From 1999 to 2000, Shane was co-founder, Vice-President and Chief Technology Officer of MDS Ocata. In 1999 Shane was a Visiting Research Scientist at the Samuel Lunenfeld Research Institute. From 1990 to 1999, he held several positions at Allelix Biopharmaceuticals, Inc. (Now NPS Allelix Inc., Nasdaq:NPSP) including Principal Scientist, Manager of New Technologies and Manager of Molecular and Structural Biology.

Site Map                                              Cytognomix.com ®                                                                      15-March-2011

Management